[(4-叔丁氧羰基哌嗪)甲基]三氟硼酸钾 | 936329-97-4

• 物质功能分类: 有机原料 - 有机氟化合物 - 氟硼酸钾系列
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: [(4-叔丁氧羰基哌嗪)甲基]三氟硼酸钾
• 中文别名: (4-叔丁氧羰基哌嗪-1-基)甲基三氟硼酸钾；(4-BOC-1-哌嗪基)甲基三氟硼酸钾；钾1-三氟硼酸甲基-4-(NBOC)-哌嗪
• 英文名称: potassium (4-tert-butoxycarbonylpiperazin-1-yl)methyltrifluoroborate
• 英文别名: potassium 4-(trifluoroboratomethyl)piperazine-1-carboxylic acid tert-butyl ester；potassium (4-[(tert-butoxy)carbonyl]piperazin-1-ylmethyl)trifluoroboranuide；potassium (4-boc-piperazin-1-yl)methyltrifluoroborate；potassium {[4-(tert-butoxycarbonyl)-1-piperazinyl]methyl}(trifluoro)borate；potassium 1-trifluoroboratomethyl-4-(N-Boc) piperazine；potassium;trifluoro-[[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]methyl]boranuide
• CAS: 936329-97-4
• 化学式: C₁₀H₁₉BF₃N₂O₂*K
• 分子量: 306.178
• InChiKey: WVNSYJFWKWTVKH-UHFFFAOYSA-N

物化性质

• 熔点：
  200 °C (decomp)(Solv: acetone (67-64-1); hexane (110-54-3); ethyl ether (60-29-7))

计算性质

• 辛醇/水分配系数(LogP)：
  -1.07
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  32.8
• 氢给体数：
  0
• 氢受体数：
  7

安全信息

• 危险性防范说明：
  P261,P280,P301+P312,P302+P352,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温环境下。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Potassium (4-BOC-piperazin-1-yl)methyltrifluoroborate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Potassium (4-BOC-piperazin-1-yl)methyltrifluoroborate
CAS number: 936329-97-4

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H19BF3N2O2.K
Molecular weight: 306.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen fluoride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  [(4-叔丁氧羰基哌嗪)甲基]三氟硼酸钾 在 palladium diacetate 、 2-二环己基磷-2,4,6-三异丙基联苯 盐酸 、 caesium carbonate 、 N,N-二异丙基乙胺 、 异丙醇 作用下， 以 四氢呋喃 、 水 、 甲苯 为溶剂， 反应 26.0h， 生成 (R)-7-[4-(3-dimethylamino-pyrrolidine-1-carbonyl)-piperazin-1-ylmethyl]-1-methyl-1H-indole-2-carboxylic acid (5-tert-butyl-3-methanesulphonylamino-2-methoxy-phenyl)-amide
  参考文献：
  名称：

  7-(Piperazine-1-Ymethyl)-1H-Indole-2-Carboxylic Acid (Phenyl)-Amide Derivatives and Allied Compounds as P38 Map Kinase Inhibitors for the Treatment of Respiratory Diseases

  摘要：

  本发明提供了根据通用公式(I)的化合物，这些化合物被建议用于治疗呼吸系统疾病，特别是哮喘和慢性阻塞性肺病(COPD)。

  公开号：

  US20110269737A1
• 作为产物：
  描述：

  (4-Boc-1-哌嗪-1-基甲基)三氟硼酸内盐 在 potassium phosphate 作用下， 以 丙酮 为溶剂， 生成 [(4-叔丁氧羰基哌嗪)甲基]三氟硼酸钾
  参考文献：
  名称：

  Reinvestigation of Aminomethyltrifluoroborates and Their Application in Suzuki−Miyaura Cross-Coupling Reactions

  摘要：

  A reinvestigation into the chemical composition of potassium aminomethyltrifluoroborates is reported. These trifluoroborato salts have been reassigned as zwitterionic ammoniomethyltrifluoroborates. Minor adjustments to the previously disclosed reaction conditions are reported that permit a similar level of activity as nucleophiles in Suzuki-Miyaura cross-coupling reactions.

  DOI：

  10.1021/jo2001066

文献信息

• [EN] AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION<br/>[FR] DÉGRONIMÈRES DE C3-GLUTARIMIDE LIÉS À UNE AMINE POUR LA DÉGRADATION DE PROTÉINES CIBLES
  申请人：C4 THERAPEUTICS INC

  公开号：WO2017197051A1

  公开（公告）日：2017-11-16

  This invention provides amine-linked C3-glutarimide Degronimers and Degrons for therapeutic applications as described further herein, and methods of use and compositions thereof as well as methods for their preparation.

  这项发明提供了胺连接的C3-戊二酰亚胺Degronimers和Degrons，用于治疗应用，如本文进一步描述的，以及它们的使用方法、组合物以及它们的制备方法。
• Mastering tricyclic ring systems for desirable functional cannabinoid activity
  作者：Ravil R. Petrov、Lindsay Knight、Shao-Rui Chen、Jim Wager-Miller、Steven W. McDaniel、Fanny Diaz、Francis Barth、Hui-Lin Pan、Ken Mackie、Claudio N. Cavasotto、Philippe Diaz

  DOI：10.1016/j.ejmech.2013.09.038

  日期：2013.11

  Compound 64 had potent inhibitory effects on pain hypersensitivity in a rat model of neuropathic pain. Other potent and CB2 receptor–selective compounds, including compounds 63 and 68, and a selective CB1 agonist, compound 74 were also discovered. In addition, we identified the CB2 ligand 35 which failed to promote CB2 receptor internalization and inhibited compound CP55,940-induced CB2 internalization despite

  人们对使用大麻素受体 2 (CB2) 激动剂治疗神经性疼痛和其他适应症越来越感兴趣。为了继续我们正在进行的旨在开发新的小分子大麻素配体的计划，我们合成了一系列新型咔唑和 γ-咔啉衍生物。新合成的化合物的亲和力通过对人 CB2 大麻素受体和大鼠 CB1 大麻素受体的竞争性放射性配体置换试验确定。使用受体内化和 [ 35 S] GTP-γ-S 测定法表征对人 CB1 和 CB2 受体的功能活性和选择性。咔唑系列的构效关系和优化研究导致发现了非选择性 CB1 和 CB2 激动剂，化合物4. 我们随后为提高该先导化合物的 CB2 选择性所做的研究工作导致了 CB2 选择性化合物64的发现，该化合物可强力内化 CB2 受体。在神经性疼痛的大鼠模型中，化合物64对疼痛超敏反应具有强效抑制作用。还发现了其他有效的 CB2 受体选择性化合物，包括化合物63和68，以及选择性 CB1 激动剂，化合物74。此外，我们还鉴定了
• Aminomethylation via Cyclopalladated-Ferrocenylimine-Complexes-Catalyzed Suzuki-Miyaura Coupling of Aryl Halides with Potassium N,N-Dialkylaminomethyltrifluoroborates
  作者：Yangjie Wu、Yusheng Wu、Dapeng Zou、Hongmeng Cui、Lijin Qin、Jingya Li

  DOI：10.1055/s-0030-1259331

  日期：2011.2

  Using cyclopalladated ferrocenylimine complexes (1-3 mol%) as catalysts, the Suzuki-Miyaura coupling of potassium N,N-dialkylaminomethyltrifluoroborates with aryl and heteroaryl halides were carried out in a 10:1 THF-H2O mixture at 80 ˚C in the presence of Cs2CO3 (3.0 equiv) as base, giving the desired cross-coupling products in 14-87% yields. A variety of potassium alkyltrifluoroborates were also examined.

  使用环钯化二茂铁亚胺配合物（1-3摩尔%）作为催化剂，在Cs2CO3（3.0当量）作为碱的存在下，在80 ℃的10:1 THF-H2O混合物中，进行钾N,N-二烷基氨基甲基三氟硼酸盐与芳基和杂芳基卤化物的铃木-宫浦偶联反应，得到了所需的交叉偶联产物，产率为14-87%。还研究了各种烷基三氟硼酸钾。
• Cu(II)-Catalyzed <i>ortho</i>-Selective Aminomethylation of Phenols
  作者：Jin-Ling Dai、Nan-Qi Shao、Jin Zhang、Run-Ping Jia、Dong-Hui Wang

  DOI：10.1021/jacs.7b06785

  日期：2017.9.13

  A Cu(II)-catalyzed ortho-selective functionalization of free phenols with trifluoroborates to afford Csp2-Csp3 coupling products under mild conditions has been developed. A variety of functional groups on the phenol and the potassium aminomethyltrifluoroborate substrates were found compatible, furnishing the corresponding products in moderate to excellent yields. A single-electron transfer radical

  已经开发出一种 Cu(II) 催化的游离酚与三氟硼酸盐的邻位选择性官能化，以在温和条件下提供 Csp2-Csp3 偶联产物。发现苯酚和氨基甲基三氟硼酸钾底物上的各种官能团是相容的，以中等至极好的收率提供相应的产品。提出了一种涉及六元过渡态的单电子转移自由基偶联机制，以合理化反应中的高水平邻位选择性。该协议提供了对邻氨基甲基取代酚、非天然氨基酸和其他生物活性小分子的直接访问。
• [EN] TARGETED THERAPEUTICS<br/>[FR] THÉRAPEUTIQUE CIBLÉE
  申请人：SYNTA PHARMACEUTICALS CORP

  公开号：WO2015038649A1

  公开（公告）日：2015-03-19

  The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.

  本发明提供了包括与将效应子导向至感兴趣的生物靶点的结合基团共轭的药理化合物。同样，本发明提供了包括这些化合物的组合物、试剂盒和方法（例如治疗、诊断和成像）。这些化合物可以被描述为蛋白质相互作用结合基团-药物共轭（SDC-TRAP）化合物，其中包括蛋白质相互作用结合基团和效应子。例如，在针对治疗癌症的某些实施方式中，SDC-TRAP可以包括Hsp90抑制剂共轭到细胞毒性药剂作为效应子。